You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

HER2-positive breast cancer

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Breast Cancer Female Trial (Pyrotinib and Trastuzumab)

Not yet recruiting
  • Breast Cancer Female
  • Pyrotinib and Trastuzumab
  • (no location specified)
Sep 11, 2023

Early On-treatment Transcriptional Profiling as Predictor of

Recruiting
  • HER2-positive Breast Cancer
  • +2 more
  • Trastuzumab (neoadjuvant)
  • +2 more
  • Hospitalet de Llobregat, Barcelona, Spain
    Institut Català d'Oncologia l'Hospitalet
Jun 12, 2023

Breast Cancer Invasive Trial (pyrotinib)

Not yet recruiting
  • Breast Cancer Invasive
  • (no location specified)
Jun 18, 2023

Sentinel Lymph Node Biopsy in Initially Lymph Node-positive,

Completed
  • Breast Cancer
  • Sentinel Lymph Node
  • Test cohort
  • Fuzhou, Fujian, China
    Chuan Wang
Nov 25, 2023

HER2-positive Breast Cancer Trial (Standard of Care Adjuvant Breast Radiation, Standard of Care HER2-targeted Therapy Without

Not yet recruiting
  • HER2-positive Breast Cancer
  • Standard of Care Adjuvant Breast Radiation
  • Standard of Care HER2-targeted Therapy Without Adjuvant Breast Radiation
  • (no location specified)
Jan 20, 2023

HER2-positive Metastatic Breast Cancer, Stage IV Breast Cancer Trial in Miami (Discontinuation of Anti-HER-2 Maintenance

Recruiting
  • HER2-positive Metastatic Breast Cancer
  • Stage IV Breast Cancer
  • Discontinuation of Anti-HER-2 Maintenance Treatment
  • Miami, Florida
    University of Miami
Jul 17, 2023

Breast Cancer, Brain Metastases, Radiotherapy Trial in Shanghai (Combination use of SRT with T-DXd)

Not yet recruiting
  • Breast Cancer
  • +2 more
  • Combination use of SRT with T-DXd
  • Shanghai, China
    Fudan University Shanghai Cancer Center
Oct 14, 2023

Breast Cancer Trial in Taizhou (Pyrotinib)

Recruiting
  • Breast Cancer
  • Taizhou, Zhejiang, China
    Taizhou Hospital
May 26, 2023

t Pathologic Complete Response Observed in HER2 Positive Breast

Completed
  • HER2+ Breast Cancer
  • Rawalpindi, Punjab, Pakistan
    Rawalpindi Medical University
Jun 26, 2023

Tumor Bed Boost Radiotherapy in HER2 Positive Breast Cancer

Recruiting
  • Breast Cancer
  • Whole breast irradiation +/- tumor bed boost
  • Seoul, Korea, Republic of
    Samsung Medical Center
May 30, 2023

HER-2 Positive Breast Cancer Trial in Tianjin (TCbHP VS ddEC-THP)

Recruiting
  • HER-2 Positive Breast Cancer
  • TCbHP VS ddEC-THP
  • Tianjin, Tianjin, China
    Breast Oncology, Tianjin Medical University Cancer Institute and
May 15, 2023

Breast Cancer, HER2-positive Breast Cancer Trial in Zhengzhou (Albumin paclitaxel+trastuzumab+pyrrolitinib,

Active, not recruiting
  • Breast Cancer
  • HER2-positive Breast Cancer
  • Zhengzhou, Henan, China
    Henan cancer hospital
Jun 23, 2023

Early-stage Breast Cancer, HER2-positive Breast Cancer, Adjuvant Treatment After Trastuzumab Trial in Guangzhou (Trastuzumab and

Recruiting
  • Early-stage Breast Cancer
  • +4 more
  • Trastuzumab and nelatinib
  • Trastuzumab and Parstuzumab
  • Guangzhou, China
    Sun Yat-sen University Sun Yat-sen Memorial Hospital
Mar 12, 2023

Breast Cancer With Brain Metastases Trial in Wuhan (pyrotinib+capecitabine+bevacizumab)

Recruiting
  • Breast Cancer With Brain Metastases
  • Wuhan, Hubei, China
    Tongji Hospital Affiliated of Tongji Medical College Huazhong Un
Nov 22, 2023

Breast Cancer Trial in Xi'an (Disitamab Vedotin plus pyrotinib or naratinib)

Not yet recruiting
  • Breast Cancer
  • Disitamab Vedotin plus pyrotinib or naratinib
  • Xi'an, Shaanxi, China
    Xi'an International Medical Center Hospital
Aug 27, 2023

Pyrotinib in Neoadjuvant Therapy for HER2-positive Breast Cancer

Not yet recruiting
  • HER2-positive Breast Cancer
  • Changsha, Hunan, China
    Hunan Cancer Hospital
Sep 28, 2022

Pyrotinib Plus Capecitabine for Adjuvant Treatment of HER2

Recruiting
  • HER2-positive Breast Cancer
  • Early-stage Breast Cancer
  • pyrotinib combined with Capecitabine
  • treatment of physician's choice
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
Sep 6, 2023

HER2-positive Breast Cancer Trial in Nanjing (HS022, Trastuzumab, Vinorelbine Bitartrate)

Completed
  • HER2-positive Breast Cancer
  • Nanjing, Jiangsu, China
    Jiangsu Province People's Hospital (First Affiliated Hospital of
Oct 25, 2023

HER2-positive Breast Cancer Trial in Shanghai (SYSA1901, Pertuzumab, Trastuzumab)

Recruiting
  • HER2-positive Breast Cancer
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center
Feb 8, 2023

HER2-positive Breast Cancer Trial in Shanghai (68Ga/131I-SGMIB-5F7)

Not yet recruiting
  • HER2-positive Breast Cancer
  • 68Ga/131I-SGMIB-5F7
  • Shanghai, China
    Huashan Hospital
Aug 1, 2023

HER2-positive Breast Cancer Trial in Amsterdam (Trastuzumab deruxtecan)

Not yet recruiting
  • HER2-positive Breast Cancer
  • Trastuzumab deruxtecan
  • Amsterdam, Netherlands
    Antoni van Leeuwenhoek
Aug 7, 2023

HER2-positive Breast Cancer Trial (Thero2-01S22, Placebo)

Not yet recruiting
  • HER2-positive Breast Cancer
  • (no location specified)
Jan 13, 2023

Advanced Breast Cancer, Objective Response Rate, Trastuzumab Emtansine Trial in Nanjing (Trastuzumab Emtansine (T-DM1))

Recruiting
  • Advanced Breast Cancer
  • +2 more
  • Trastuzumab Emtansine (T-DM1)
  • Nanjing, Jiangsu, China
    JiangSu Province Hospital/ The First Affiliated Hospital of Nanj
Nov 5, 2023

Breast Cancer, HER2-positive Breast Cancer Trial in São Paulo (PHESGO)

Not yet recruiting
  • Breast Cancer
  • HER2-positive Breast Cancer
  • São Paulo, Brazil
    Centro Paulista de Oncologia (Oncoclínicas)
Oct 3, 2023

Early-stage HER2-positive Breast Cancer, Treated With Neratinib

Recruiting
  • Breast Cancer
  • +2 more
    • Bouge, Belgium
      Clinique Saint-Luc Bouge
    Oct 25, 2022